Olmesartan medoxomil: recent clinical and experimental acquisitions

Bibliography

• Laeis P, Püchler K, Kirch W. The pharmacokinetic and metabolic profile of olmesartan medoxomil limits the risk of clinically relevant drug interaction. J Hypertens 2001;19(Suppl):S21-32
   PubMedGoogle Scholar
• Wehling M. Can the pharmacokinetic characteristics of olmesartan medoxomil contribute to the improvement of blood pressure control? Clin Ther 2004;26 (Suppl A):A21-7
   PubMed Web of Science ®Google Scholar
• Neutel JM. Clinical studies of CS-866, the newest angiotensin II receptor antagonist. Am J Cardiol 2001;87(Suppl):37C-43C
   PubMed Web of Science ®Google Scholar
• Schwocho LR, Masonson HN. Pharmacokinetics of CS-866, a new angiotensin II receptor blocker, in healthy subjects. J Clin Pharmacol 2001;41:515-27
   PubMed Web of Science ®Google Scholar
• von Bergmann K, Laeis P, Püchler K, et al. Olmesartan medoxomil: influence of age, renal and hepatic function on the pharmacokinetics of olmesartan medoxomil. J Hypertens 2001;19(Suppl):S33-40
   Web of Science ®Google Scholar
• Burnier M, Brunner HR. Angiotensin II receptor antagonists. Lancet 2000;355(9204):637-45
   PubMed Web of Science ®Google Scholar
• Le MT, Pugsley MK, Vauquelin G, Van Liefde I. Molecular characterisation of the interactions between olmesartan and telmisartan and the human angiotensin II AT1 receptor. Br J Pharmacol 2007;151(7):952-62
   PubMed Web of Science ®Google Scholar
• Jones MR, Sealey JE, Laragh JH. Effects of angiotensin receptor blockers on ambulatory plasma rennin activity in healthy, normal subjects during unrestricted sodium intake. Am J Hypertens 2007;20(8):907-16
   PubMed Web of Science ®Google Scholar
• Giles TD, Robinson TD. Effects of olmesartan medoxomil on systolic blood pressure and pulse pressure in the management of hypertension. Am J Hypertens 2004;17(8):690-5
   PubMed Web of Science ®Google Scholar
• Fernandes-Santos C, de Souza Mendonça L, Mandarim-de-Lacerda CA. Favorable cardiac and aortic remodeling in olmesartan-treated spontaneously hypertensive rats. Heart Vessels 2009;24(3):219-27
   PubMed Web of Science ®Google Scholar
• Fliser D, Wagner KK, Loos A, et al. Chronic angiotensin II receptor blockade reduces (intra)renal vascular resistance in patients with type 2 diabetes. J Am Soc Nephrol 2005;16(4):1135-40
   PubMed Web of Science ®Google Scholar
• Smith RD, Yokoyama H, Averill DB, et al. The protective effects of angiotensin II blockade with olmesartan medoxomil on resistance vessel remodeling (The VIOS study): rationale and baseline characteristics. Am J Cardiovasc Drugs 2006;6(5):335-42
   PubMedGoogle Scholar
• Stumpe KO, Agabiti-Rosei E, Zielinski T, et al. Carotid intima-media thickness and plaque volume changes following 2-year angiotensin II-receptor blockade. The Multicentre Olmesartan atherosclerosis Regression Evaluation (MORE) study. Ther Adv Cardiovasc Dis 2007;1(2):97-106
   PubMedGoogle Scholar
• Fukuda M, Yamanaka T, Mizuno M, et al. Angiotensin II type 1 receptor blocker, olmesartan, restores nocturnal blood pressure decline by enhancing daytime natriuresis. J Hypertens 2008;26(3):583-8
   PubMed Web of Science ®Google Scholar
• Chrysant SG, Marbury TC, Robinson TD. Antihypertensive efficacy and safety of olmesartan medoxomil compared with amlodipine for mild-to-moderate hypertension. J Hum Hypertens 2003;17(6):425-32
   PubMed Web of Science ®Google Scholar
• Fliser D, Buchholz K, Haller H, et al. Antiinflammatory effects of angiotensin II subtype 1 receptor blockade in hypertensive patients with microinflammation. Circulation 2004;110(9):1103-7
   PubMed Web of Science ®Google Scholar
• Ogawa H, Kim-Mitsuyama S, Jinnouchi T, et al. Rationale, design and patient baseline characteristics of OlmeSartan and calcium antagonists randomized (OSCAR) study: a study comparing the incidence of cardiovascular events between high-dose angiotensin II receptor blocker (ARB) monotherapy and combination therapy of ARB with calcium channel blocker in Japanese elderly high-risk hypertensive patients (ClinicalTrials. gov no. NCT00134160). Hypertens Res 2009;32(7);575-80
   PubMed Web of Science ®Google Scholar
• Dahlöf B, Devereux RB, Kjeldsen SE, et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002;359(9311):995-1003
   PubMed Web of Science ®Google Scholar
• Viberti G, Nigel MW, for the Microalbuminuria Reduction With VALsartan (MARVAL) Study Investigators. Microalbuminuria reduction with valsartan in Ptients with type 2 diabetes mellitus. A blood pressure independent effect. Circulation 2002;106:672-8
   PubMed Web of Science ®Google Scholar
• Brenner BM, Cooper ME, de Zeeuw D, et al. The losartan renal protection study–rationale, study design and baseline characteristics of RENAAL (Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan). J Renin Angiotensin Aldosterone Syst 2000;1:328-35
   PubMedGoogle Scholar
• Berl T, Humsicker LG, Lewis JB, et al. Impact of achieved blood pressare on cardiovascular outcomes in the Irbesartan Diabetic Nephropathy Trial. J Am Soc Nephrol 2005;16:2170-9
   PubMed Web of Science ®Google Scholar
• Parving HH, Lehnert H, Bröchner-Mortensen J, et al. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 2001;345(12):870-8
   PubMed Web of Science ®Google Scholar
• Haller H, Viberti GC, Mimran A, et al. Preventing microalbuminuria in patients with diabetes: rationale and design of the Randomised Olmesartan and Diabetes Microalbuminuria Prevention (ROADMAP) study. J Hypertens 2006;24(2):403-8
   PubMed Web of Science ®Google Scholar
• Püchler K, Laeis P, Gunther A, et al. Safety, tolerability and efficacy of the new oral angiotensin II (AT1)-receptor antagonist CS-866 in patients with mild to moderate hypertension [abstract no. P.11]. J Hum Hypertens 1999;13(Suppl 3):4
   Google Scholar
• Masonson HN, Punzi HA, Neutel JM, et al. CS-866 (angiotensin II receptor antagonist): a double-blind study using ambulatory blood pressure monitoring in hypertensive patients [abstract no. D035]. Am J Hypertens 1998;11(4 Pt 2):77
   Web of Science ®Google Scholar
• Püchler K, Laeis P, Stumpe KO. A comparison of the efficacy and safety of the oral angiotensin II antagonist olmesartan medoxomil with those of atenolol in patients with moderate to severe hypertension under continuous treatment with hydrochlorothiazide [abstract no. P2.175]. J Hypertens 2001;19(Suppl 2):153
   Google Scholar
• Neutel JM. Clinical studies of CS-866, the newest angiotensin II receptor antagonist. Am J Cardiol 2001;87(8A):37-43
   PubMed Web of Science ®Google Scholar
• Benicar® package insert. Sankyo Pharma, Inc, New York
   Google Scholar
• Israili ZH, Hall WD. Cough and angioneurotic edema associated with angiotensin-converting enzyme inhibitor therapy: a review of the literature and pathophysiology. Ann Intern Med 1992;117:234-42
   PubMed Web of Science ®Google Scholar
• Kottke TE, Stroebel RJ, Hoffmann RS. JNC 7: it's more than high blood pressure. JAMA 2003;289(19):2573-5
   PubMed Web of Science ®Google Scholar
• Benson S, Vance-Bryan K, Raddatz J. Time to patient discontinuation of antihypertensive drugs in different classes. Am J Health Syst Pharm 2000;57(1):51-4
   PubMed Web of Science ®Google Scholar
• Dzau VJ, Antman EM, Black HR, et al. The cardiovascular disease continuum validated: clinical evidence of improve patient outcomes: part I: Pathophysiology and clinical trial evidence (risk factors trough stable coronary artery disease). Circulation 2006;114(25):2850-70
   PubMed Web of Science ®Google Scholar
• Destro M, Scabrosetti R, Vanasia A, Mugellini A. Comparative efficacy of valsartan and olmesartan in mild-to-moderate hypertension: results of 24-hour ambulatory blood pressure monitoring. Adv Ther 2005;22(1):32-43
   PubMed Web of Science ®Google Scholar
• Dolan E, Stanton A, Thijs L, et al. Superiority of ambulatory over clinic blood pressure measurements in predicting mortality: the Dublin outcome Study. Hypertension 2005;46(1):156-61
   PubMed Web of Science ®Google Scholar
• Pickering TG. When and how to use self (home) and ambulatory blood pressure monitoring. J Am Soc Hypertens 2008;2(3):119-24
   PubMed Web of Science ®Google Scholar
• van der Hoeven NV, van den Born BJ, Cammenga M, van Montfrans GA. Poor adherence to home blood pressure measurements schedule. J Hypertens 2009;27(2):275-9
   PubMed Web of Science ®Google Scholar
• Ferrario CM. Preferential effects of angiotensin receptor blocker (ARB) therapy on vascular structure: results of the Vascular Improvement with Olmesartan medoxomil Study (VIOS) [abstract no.SS1-2]. J Hypertens 2006;24(Suppl 6):414
   Google Scholar
• Yokoyama H, Smith RD, Averill DB, et al. Vascular improvement with olmesartan medoxomil [abstract no. P-42]. Am J Hypertens 2005;18(5 Pt 2):23
   PubMed Web of Science ®Google Scholar
• Benicar® tablets (olmesartan medoxomil): US prescribing information. Parsippany (NJ): Daiichi Sankyo Inc., 2006
   Google Scholar
• Daiichi Sankyo UK Limited. Olmetec Plus flm-coated tablets: summary of product characyeristics [online]. Available from: http://emc.medicines.org.uk [Accessed 6 Mar 2006]
   Google Scholar
• Neutel JM. Clinical studies of CS-866, the newest angiotensin II receptor antagonists. Am J Cardiol 2001;87(Suppl 8A):37-43
   PubMed Web of Science ®Google Scholar
• Püchler K, Laeis P, Stumpe KO. Blood pressure response, but not adverse event incidence, correlates with dose of angiotensin II antagonist. J Hypertens 2001;19(Suppl 1):41-8
   PubMed Web of Science ®Google Scholar
• Brunner HR. Clinical efficacy and tolerability of olmesartan. Clin Ther 2004;26(Suppl A):28-32
   PubMed Web of Science ®Google Scholar
• Daiichi Sankyo UK Limited. Olmetec Plus flm-coated tablets: summary of product characyeristics [online]. Available from: http://emc.medicines.org.uk [Accessed 6 Mar 2007]
   Google Scholar
• Benicar HCT tablets (olmesartan medoxomil – hydrochlorothiazide): US prescribing information. Parsippany (NJ): Daiichi Sankyo Inc., 2006
   Google Scholar